Importantly, TGF-β1 and BMP2/4 treatment had inhibitory effects on cell proliferation; however, miR-155 overexpression enabled CD34+ CML cells to evade the anti-proliferative effects of TGF-β1 and BMPs. This evidence concerns the gene BMP2 and chronic myelogenous leukemia, BCR-ABL1 positive.